StockData
PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Prelude Therapeutics Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.39+0.13 (+3.99%)

Close on Oct 19, 2026

Market cap
$333.54M
P/E (TTM)
–
Dividend yield
–

Prelude Therapeutics Inc revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Prelude Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.